TITAN Study Design
TITAN: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of ERLEADA® + ADT vs placebo + ADT in patients with diverse clinical characteristics1,2
Patients in TITAN had newly diagnosed mCSPC or relapsed metastatic disease after an initial diagnosis of localized disease. Patients with visceral (ie, liver or lung) metastases as the only sites of metastases were excluded.2
Selected baseline patient characteristics1,2
|Median age||68 (range: 43 to 94 years)|
|Prior prostatectomy or radiation therapy of the prostate, or both||16%|
|Prior first-generation antiandrogen*||68%|
|Gleason score at diagnosis ≥8||67%|
|Volume of disease|
*Eg, bicalutamide, flutamide, or nilutamide.
†Patients who received prior docetaxel must have met the following criteria: (1) received a maximum of 6 cycles of docetaxel therapy for mCSPC; (2) received the last dose of docetaxel ≤2 months prior to randomization; (3) maintained a response to docetaxel of stable disease or better prior to randomization.2
‡High volume of disease was defined as metastases involving the viscera with 1 bone lesion or the presence of 4 or more bone lesions, at least 1 of which must be in a bony structure beyond the vertebral column and pelvic bones.1
Dual primary endpoints in TITAN2
- Overall survival
- Radiographic progression-free survival (rPFS)
Selected secondary endpoint in TITAN2
- Time to cytotoxic chemotherapy
ADT = androgen deprivation therapy; GnRH = gonadotropin-releasing hormone; mCSPC = metastatic castration-sensitive prostate cancer; TITAN = Targeted Investigational Treatment Analysis of Novel Antiandrogen.
1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
2. Chi KN, Agarwal N, Bjartell A, et al; for the TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24.